NCT01132326View on ClinicalTrials.gov

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Primary Autonomic FailureDopamine Beta Hydroxylase DeficiencyNon-Diabetic NeuropathyNeurogenic Orthostatic Hypotension
Interventions
DRUG

Droxidopa

Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months

Sponsors
All Listed Sponsors
lead

Chelsea Therapeutics

INDUSTRY